ClinicalTrials.Veeva

Menu

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

R

Rambam Health Care Campus

Status and phase

Unknown
Phase 4

Conditions

NIDDM

Treatments

Drug: candesartan

Study type

Interventional

Funder types

Other

Identifiers

NCT00192803
ACE2.CTIL

Details and patient eligibility

About

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent
  • Non-smokers
  • Type II DM diagnosed patients
  • Blood pressure < 135/90
  • Serum HbA1C > 7%
  • Serum creatinine < 1mg%
  • Urine microalbumin < 300 mg/day
  • Body mass index (BMI) < 35 kg/m2

Exclusion criteria

  • Insulin-dependent diabetic patients
  • Patient with persistent microalbuminuria
  • Patient with history of severe hypertension
  • Congestive heart failure
  • Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
  • Patient with major hepatic disease

Trial design

Primary purpose

Educational/Counseling/Training

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Shlomo Keidar, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems